The University of Edinburgh analyzed more than 6,000 genomes in a year, an effort made possible by a computing center dubbed a "genome factory" by its director.
The initiative will leverage existing standards to deliver genomic information to electronic medical record systems more effectively.
Proponents believe the Million European Genomes Alliance will spur research, stimulate the life sciences economy, and ultimately improve clinical care.
A 400-sample retrospective analysis in invasive breast cancer will inform a basket trial that the Ontario Institute for Cancer Research hopes to soon launch.
Editas has paid $1 million to test-drive Adverum's viral vectors in clinical gene editing and $1 million for an option on an exclusive license.
The firm will provide DNA from at least 50 mouse cell lines for use in a PCR-based validation assay.
The service, which 23andMe has been piloting for some time, would also give participants access to genetic data in return for their contribution to research.
The partners will characterize patient immune response to two new investigational immunotherapies from Argos Therapeutics.
Caribou will license its CRISPR technology to Genus to help it create pigs that are resistant to Porcine Reproductive and Respiratory Syndrome Virus.
The company also said it has signed a collaboration deal with Bristol-Myers Squibb to evaluate the efficacy of immuno-oncology molecular profiling.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.